{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:51:23Z","timestamp":1791492683266,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.semarthrit.2026.152938","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:02:46Z","timestamp":1769875366000},"page":"152938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Flare incidences of pre-existing rheumatologic diseases in patients with solid tumors receiving immune checkpoint inhibitors: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9308-0530","authenticated-orcid":false,"given":"Kenji","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takemichi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1406-2352","authenticated-orcid":false,"given":"Yu","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2026.152938_bib0001","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with Immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0003","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.immuni.2016.04.017","article-title":"Co-stimulatory and Co-inhibitory pathways in autoimmunity","volume":"44","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0004","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0005","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis vs rheumatoid arthritis: A comparative review","author":"Georgios","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0006","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13075-022-02737-6","article-title":"Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis","volume":"24","author":"S\u00f8rensen","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102687","article-title":"Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies","volume":"19","author":"Xie","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0008","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0009","first-page":"7747","article-title":"Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis","volume":"29","author":"Yamaguchi","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0010","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: A single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114148","article-title":"A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease","volume":"207","author":"Lopez-Olivo","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0012","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide","volume":"71","author":"Tison","year":"2019","journal-title":"Multicent Cohort Study Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0013","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0014","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0015","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.40397","article-title":"Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience","volume":"70","author":"Richter","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0016","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1756-185X.13444","article-title":"Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy","volume":"22","author":"Liew","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105457","article-title":"Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer","volume":"90","author":"Melia","year":"2023","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0018","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00262-021-02851-5","article-title":"Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology","volume":"70","author":"Hoa","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0019","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/10781552231167824","article-title":"Immunosuppressive therapy management in cancer patients with autoimmune diseases treated with immune checkpoint inhibitors: A case series and systematic literature review","volume":"30","author":"Wuyts","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0020","first-page":"267","article-title":"Risk of toxicity after initiating immune checkpoint inhibitor treatment in patients with rheumatoid arthritis","volume":"27","author":"Efuni","year":"2021","journal-title":"JCR: J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0021","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/CJI.0000000000000377","article-title":"Safety and clinical outcomes of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases","volume":"44","author":"Yeung","year":"2021","journal-title":"J Immunother"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0022","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"K\u00e4hler","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003066","article-title":"Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy","volume":"9","author":"Halle","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0024","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1007\/s00432-021-03610-w","article-title":"Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience","volume":"147","author":"Bhatlapenumarthi","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0025","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.semarthrit.2018.10.012","article-title":"Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience","volume":"48","author":"Mooradian","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0026","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejca.2021.10.018","article-title":"Anti\u2013programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study","volume":"160","author":"Panhaleux","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0027","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2217\/imt-2020-0272","article-title":"Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis","volume":"13","author":"Kim","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0028","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejca.2020.07.023","article-title":"Safety and efficacy of atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced\/metastatic urinary tract carcinoma","volume":"138","author":"Loriot","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0029","first-page":"338","article-title":"A safety analysis of programmed death 1 pathway inhibitors in patients with solid tumor malignancies and preexisting autoimmune disease","volume":"28","author":"Higgins","year":"2022","journal-title":"JCR: J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002121","article-title":"Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders","volume":"9","author":"Brown","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152460","article-title":"Immune checkpoint inhibitor therapy in patients with cancer and pre-existing systemic sclerosis","volume":"67","author":"Wallwork","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0032","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","article-title":"Rheumatic immune-related adverse events secondary to anti\u2013programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series","volume":"105","author":"Mitchell","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000538","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study","volume":"8","author":"Martinez Chanza","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0034","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3892\/ol.2023.13963","article-title":"Toxicity, disease management and outcome of treatment with immune checkpoint inhibitors by sex in patients with cancer and preexisting autoimmune disease","volume":"26","author":"Liu","year":"2023","journal-title":"Oncol Lett"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0036","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: A real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0037","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s41927-022-00297-5","article-title":"Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy","volume":"6","author":"Lusa","year":"2022","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0038","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death\u20131 pathway inhibitors among patients with non\u2013Small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152335","article-title":"Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer","volume":"64","author":"McCarter","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0041","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211006963","article-title":"Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis","volume":"13","author":"Verspohl","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0042","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0043","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1007\/s00432-023-04582-9","article-title":"Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases","volume":"149","author":"Pizuorno Machado","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0044","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12885-024-12256-z","article-title":"Immune checkpoint inhibitors in cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0045","article-title":"Immune checkpoint inhibitors in the treatment of patients with cancer and preexisting psoriasis: A systematic review and meta-analysis of observational studies","volume":"12","author":"Yu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0046","article-title":"The efficacy and safety of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease","volume":"11","author":"Tang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0047","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/cei.12949","article-title":"Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1","volume":"188","author":"Bommarito","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0048","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/art.37714","article-title":"Impact of the CTLA-4\/CD28 axis on the processes of joint inflammation in rheumatoid arthritis","volume":"65","author":"K\u00f6rmendy","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0049","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.autrev.2013.01.001","article-title":"Advances in CTLA-4-ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis","volume":"12","author":"Cutolo","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0050","doi-asserted-by":"crossref","first-page":"19396","DOI":"10.1073\/pnas.0806855105","article-title":"Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis","volume":"105","author":"Flores-Borja","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0051","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0052","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","article-title":"Systemic Lupus Erythematosus pathogenesis: interferon and beyond","volume":"41","author":"Caielli","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.semarthrit.2026.152938_bib0053","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.41949","article-title":"Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer","volume":"74","author":"Cunningham-Bussel","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226000272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:41:51Z","timestamp":1791492111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226000272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":53,"alternative-id":["S0049017226000272"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152938","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flare incidences of pre-existing rheumatologic diseases in patients with solid tumors receiving immune checkpoint inhibitors: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.152938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152938"}}